asa guidelines for glp 1 agonists Glucagon-Like Peptide-1 Receptor in Perioperative Care ASA: Hold GLP-1 Agonists Before

A., Elahi, D., Shen, Y

The NAION incidence was 20 events in the semaglutide group compared to 3 in the non-GLP-1 RA group

Tirzepatide which targets both GLP-1 and GIP receptors has shown even more dramatic early results: weight loss of 1020 kg and insulin dose reductions exceeding 30% in observational and phase 2 data, with improved CGM time in range

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy

It also helped clarify the three main mechanisms leading to reductions in plasma glucose concentrations: (a) glucose-dependent insulinotropic actions [5], (b) suppression of glucagon hypersecretion [7] except during episodes characterized by hypoglycemia [10], and (c) a deceleration of gastric emptying, which was found to be associated with marked effects on post-meal glycemic excursions [11]